OPKO HEALTH INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: March 3, 2025 | OPKO HEALTH, INC. | |
|---|---|---|
| By: | /s/ Phillip Frost, M.D. | |
| Phillip Frost, M.D. | ||
| Chairman of the Board and | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Phillip Frost, M.D. | Chairman of the Board and Chief Executive | March 3, 2025 |
| Phillip Frost, M.D. | Officer (Principal Executive Officer) | |
| /s/ Jane H. Hsiao, Ph.D., MBA | Vice Chairman and Chief Technical Officer | March 3, 2025 |
| Jane H. Hsiao, Ph.D., MBA | ||
| /s/ Elias A. Zerhouni, M.D. | Vice Chairman and President | March 3, 2025 |
| Elias A. Zerhouni, M.D. | ||
| /s/ Steven D. Rubin | Director and Executive Vice President – | March 3, 2025 |
| Steven D. Rubin | Administration | |
| /s/ Adam Logal | Senior Vice President, Chief Financial Officer, | March 3, 2025 |
| Adam Logal | Chief Accounting Officer and Treasurer (Principal Financial Officer) | |
| /s/ Gary J. Nabel, M.D., Ph.D. | Director, Chief Innovation Officer | March 3, 2025 |
| Gary J. Nabel, M.D., Ph.D. | ||
| /s/ Richard Krasno, Ph.D. | Director | March 3, 2025 |
| Richard Krasno, Ph.D. | ||
| /s/ Prem A. Lachman, M.D. | Director | March 3, 2025 |
| Prem A. Lachman M.D. | ||
| /s/ Roger J. Medel, M.D. | Director | March 3, 2025 |
| Roger J. Medel, M.D. | ||
| /s/ John A. Paganelli | Director | March 3, 2025 |
| John A. Paganelli | ||
| /s/ Richard C. Pfenniger, Jr. | Director | March 3, 2025 |
| Richard C. Pfenniger, Jr. | ||
| /s/ Alice Lin-Tsing Yu, M.D., Ph.D. | Director | March 3, 2025 |
| Alice Lin-Tsing Yu, M.D., Ph.D. | ||
| Exhibit Number | Description |
| 19.1 | OPKO Health, Inc. Related Party Transaction Policy. |
| 21 | Subsidiaries of the Company. |
| 23.1 | Consent of Independent Registered Public Accounting Firm. |
| 31.1 | Certification by Phillip Frost, Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the year ended December 31, 2024. |
| 31.2 | Certification by Adam Logal, Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the year ended December 31, 2024. |
| 32.1 | Certification by Phillip Frost, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the year ended December 31, 2024. |
| 32.2 | Certification by Adam Logal, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the year ended December 31, 2024. |
| Exhibit 101.INS | Inline XBRL Instance Document |
| Exhibit 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| Exhibit 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| Exhibit 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| Exhibit 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| Exhibit 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| Exhibit 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.